Hem › Burkitts lymfom › District of Columbia
Kliniska studier för Burkitts lymfom i District of Columbia
5 studier för Burkitts lymfom söker deltagare vid platser i District of Columbia.
Städer i District of Columbia
Officiell studietext (engelska)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- MedStar Georgetown University Hospital, Washington D.C.
- Children's National Medical Center, Washington D.C.
RekryterarFas 2
366 Days – 46 Years · Alla kön · Uppdaterad 2 okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- MedStar Georgetown University Hospital, Washington D.C.
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's National Medical Center, Washington D.C.
RekryterarFas 2
365 Days · Alla kön · Uppdaterad 25 sep. 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's National Medical Center, Washington D.C.
RekryterarFas 2
Ålder 1 till 30 · Alla kön · Uppdaterad 1 sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's National Medical Center, Washington D.C.
RekryterarFas 3
365 Days – 25 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03959085Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.